Navigation Links
Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic

r 2007 are forward- looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward- looking statements. Such risks and uncertainties include the following: (1) the possibility that we may not be able to successfully complete the development of ferumoxytol, or may not be able to complete the development in a timely or cost-effective manner, due to deficiencies in the design or oversight by us of these trials, the failure of our trials to demonstrate that ferumoxytol is safe and efficacious, unexpected results from our clinical sites, inadequate performance by third-party service providers, or any other factor causing an increase in expenses, a delay and/or a negative effect on the results of the clinical studies for ferumoxytol; (2) uncertainties surrounding our ability to obtain regulatory approval for ferumoxytol from the FDA; (3) the possibility that the results of past ferumoxytol studies may not be replicated in future studies; (4) the fact that we have limited sales and marketing expertise; (5) the possibility that we may not be able to raise additional capital on terms and on a timeframe acceptable to us, if at all; (6) uncertainties relating to our patents and proprietary rights; and (7) other risks identified in our Securities and Exchange Commission filings. We caution readers not to place undue reliance on any forward-looking statements which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

    Contacts:

    Kristen Galfetti (investors)

    

    (617) 498-3362


    Lynn Kettleson (media)

    

    (978) 463-7952






Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
(Date:8/21/2014)... -- Publicis Groupe customer engagement agency Rosetta today ... Industry Group Leader, has been featured in the 2014 ... people in the life-sciences industry. Those chosen for this ... technology, creativity, strategy and medicine. Hartley ... its leading Rosetta Consulting practice. In 2012, she was ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Shannon Hartley Shines in PharmaVOICE 100 2
... ROSA, Calif. , Feb. 16 Osseon Therapeutics Inc. ... Europe . The procedures were performed in Milan, Italy . ... independent medical device distributor in Europe , Osseoplasty cases are ... United Kingdom , Germany and Spain . , ...
... N.J. , Feb. 16 IntegriChain, Inc., ... the launch of its new DNA: Dynamic NextGen ... helps pharmaceutical manufacturers unlock the value of Direct Data ... Data includes those data assets typically provided to ...
Cached Medicine Technology:Osseon Launches in Europe 2IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform 2IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform 3
(Date:8/21/2014)... To sexually objectify a woman is to focus on ... sexual pleasure rather than viewing her as a complete ... long been considered a problem in the media, how ... in Psychology of Women Quarterly , a SAGE ... body is related to higher incidents of sexual pressure ...
(Date:8/21/2014)... London, UK (PRWEB) August 21, 2014 ... from USD 15.6 billion in 2014 and reach USD ... during the forecast period. The drivers of such growth ... products, rising obese and diabetic population, and surging ageing ... costs of state-of-the-art wound care products. Region-wise, North America ...
(Date:8/21/2014)... Revista, a one-stop source for healthcare ... is “on a roll.” Today, the Annapolis-based company ... Southeast, Mid-Atlantic and Midwest areas of the country ... available, comprehensive medical property database tracking these regions. ... including existing and recently added, is 34,549. This ...
(Date:8/21/2014)... News) -- Using two types of polio vaccines seems ... boost efforts to eradicate polio, a new study shows. ... found that giving the Salk inactivated poliovirus vaccine (IPV) ... live-attenuated oral poliovirus vaccine (OPV) appeared to improve their ... findings, reported in the Aug. 22 issue of the ...
(Date:8/21/2014)... (CHEST) announces the immediate release of Care of ... Disasters: CHEST Consensus Statement today in the Online ... while the global health-care community cares for patients ... to guide ethical decision-making, coordination of care, resource ... developed by over 100 clinicians and experts representing ...
Breaking Medicine News(10 mins):Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... PHILADELPHIA, Sept. 28 Independence Blue Cross,announces it ... System,and St. Mary Medical Center, both part of ... 2007. The Mercy Health System includes Mercy ... St. Agnes Continuing,Care Center, and Nazareth Hospital, as ...
... Intelligence,executive once said: "CI is like oxygen. You have ... need it is when it is in short supply." ... or have been a,client for such insights, you understand ... position in the,marketplace. By delivering high-impact analyses on competitors, ...
... New Option To Treat Morbid Obesity, CINCINNATI, ... U.S. Food and Drug Administration (FDA) approved for,marketing ... for,weight reduction and improvement in obesity-related health conditions, ... obesity. The REALIZE Band is an innovative ...
... BOZEMAN, Mont. -- Stable flies are the latest suspect that ... hundreds of pelican chicks at the Medicine Lake National Wildlife ... 1,000 pelican chicks in 2003, averaged 400 in each of ... year. , Veterinary entomologist Greg Johnson of Montana State University ...
... that minority patients generally receive a lower quality ... can these disparities be reduced? A supplement to ... and Review, published by SAGE, thoroughly explores the ... question. , The supplement features research from the ...
... ON, Sept. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC ... the next,generation of therapeutic products for inflammatory and ... million of,liabilities. Pursuant to a unanimous resolution ... to the Company by its directors, officers and ...
Cached Medicine News:Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 3Health News:Uncover Key Competitive Intelligence Insights in Webinars Hosted by Best Practices 2Health News:FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity 2Health News:FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity 3Health News:FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity 4Health News:Montana State University researchers investigate new suspect in West Nile deaths of pelicans 2
DSL-10-49200 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in serum. This kit requires no sample extraction or pretreatment...
RIA kit for the quantitative determination of autoantibodies to steroid 21-hydroxylase (21-OH) in serum....
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... by irradiation. Dimensions: 78 mm W x 152 ...
... Increased volume for use with 4, ... and V-shaped bottom permits withdrawal of nearly ... lips to dispose of excess solution. Made ... Non-sterile. Dimensions: 78 mm W x 152 ...
Medicine Products: